Drug Hunter
Drug Hunter
  • Видео 32
  • Просмотров 41 573
Mastering hERG: Med Chem Strategies for Mitigating Cardiotoxicity Risks
In the pursuit of safer drugs medicinal chemists often face the challenge of mitigating cardiotoxicity liabilities that are linked to hERG (human Ether-à-go-go-Related Gene) ion channel inhibition.
In this Coffee Chat our team discusses some of the strategies and tactics medicinal chemists use to minimize hERG-related risks during lead optimization. They explore innovative design principles for reducing hERG affinity while maintaining on-target potency and share case studies of successful implementations. This session provides valuable insights and practical approaches to addressing hERG liabilities in your programs.
Attendees submitted questions in advance and engaged with our team in a li...
Просмотров: 1 154

Видео

The Medicinal Chemist's Guide to Solving ADMET Challenges
Просмотров 1,9 тыс.Месяц назад
Early ADMET (absorption, distribution, metabolism, excretion and toxicity) profiling in small molecule drug discovery has significantly reduced later-stage failures due to inadequate pharmacokinetics and safety liabilities over the past two to three decades. A wealth of knowledge on design strategies to address common ADMET issues has been compiled in "The Medicinal Chemist’s Guide to Solving A...
2023 Drug Approval Highlights
Просмотров 1 тыс.Месяц назад
Last year, the FDA green-lit 34 new small molecule drugs, marking a year of significant breakthroughs in drug discovery. Watch this engaging Flash Talk where Dennis X. Hu, Lewis Pennington and Dennis Koester highlight the most exciting drug discovery stories and deep-dive into the most compelling case studies of small molecule drugs approved in 2023. This session explores innovative treatments ...
Coffee Chat: Unusual Motifs in Recent Clinical Candidates and Approved Drugs
Просмотров 1,4 тыс.Месяц назад
As medicinal chemists, we're all curious about the structures of clinical candidates and drugs. In this Coffee Chat Dennis Hu, Lew Pennington, and Dennis Koester, highlight selected unusual motifs in clinical candidates and approved drugs using Drug Hunter’s new Structure Search tool, demonstrating how you can use the tool to generate ideas and pressure-test your designs before synthesis or ext...
About Drug Hunter
Просмотров 364Месяц назад
Every day, companies disclose discovery strategies, tactics, challenges and solutions, but the knowledge is fragmented across journals, conferences, patents, databases, news and endless other sources, making it challenging to find and apply. Drug Hunter connects the dots, distilling industry lessons from thousands of sources into a one-of-a-kind searchable platform for drug discovery knowledge ...
Design Principles in the Beyond Rule of 5 Space
Просмотров 1,5 тыс.2 месяца назад
Modern drug discovery is now capable of targeting previously considered undruggable targets. The complexity of medicines is increasing, with many drug molecules and modalities violating at least one of Lipinski's Rule of 5 (Ro5) parameters. In the "beyond Rule of 5" (bRo5) space, unique design principles are essential. Optimizing permeability and lipophilicity is particularly challenging due to...
VC Biotech Investing and Company Creation 101
Просмотров 6532 месяца назад
Enjoy our recent conversation with Florencia Segal where we discussed the state of the biotech market. Florencia shared biotech startup success factors and common pitfalls, and what a career in venture capital entails. As an Infectious Diseases Physician-Scientist and a drug development leader, Florencia brings a unique perspective to the realm of investing. She is currently a Partner at MPM Bi...
Target Spotlight WRN Helicase
Просмотров 1,3 тыс.2 месяца назад
In this coffee chat we discussed one of our team's favorite targets: WRN helicase. During this session, the team delves into why WRN helicase has captured the attention of researchers and unpacked the intricacies of its mechanism of action. They also highlighted an intriguing approach to hit finding that has paved the way for the development of a WRN helicase inhibitor and evaluate compound dif...
Drug Hunter Case Study Overview
Просмотров 1442 месяца назад
The traditional way we learn about the latest in drug discovery is a conference presentation or a journal club. You pick a colleague, ask them to spend two weeks researching a topic, and have the whole department sit in a room for an hour while your co-worker tells you what they learned. You’d be lucky to get through one topic a quarter - IF you can find co-workers that are willing to keep volu...
Minds & Molecules: Lessons from Alzheimer's Research
Просмотров 9432 месяца назад
Despite limited success with amyloid-targeting biologics, Alzheimer's disease (AD) remains a neurodegenerative disorder in dire need of new directions and new thinking to augment ongoing approaches. Instead of seeking a single "magic bullet" for AD, a multifaceted approach is more likely to lead to success. Targets involved in neuroinflammation have emerged for the treatment of AD. 00:23 Introd...
Drug Induced Liver Injury - A Medicinal Chemist's Perspective
Просмотров 1,9 тыс.3 месяца назад
This talk provides a medicinal chemist's perspective on the current understanding of DILI mechanisms, highlight cutting-edge assay developments for a holistic assessment, and discuss strategies for predicting DILI risks. This session aims to equip medicinal chemists with working knowledge to manage DILI risks on their programs. 00:22 Introduction 02:04 Ice-breaker questions 08:27 Presentation 3...
A Guide to Generative AI for Medicinal Chemists, ​Presented by Ashwini Ghogare, Ph.D.
Просмотров 1,4 тыс.3 месяца назад
Drug Hunter's Dennis Koester, Director of Industry Research and Relations, hosts a conversation with Ashwini Ghogare, Ph.D., the Head of AI & Automation in Drug Discovery at MilliporeSigma. ​This Flash Talk explores how generative AI can streamline drug discovery workflows for medicinal chemists, from hit identification to lead optimization. 00:00 - Welcome and Introduction 03:31- Introduction ...
Meet the Drug Hunter Team
Просмотров 3413 месяца назад
In case you missed our "Meet the Team" informal coffee chat, here's your chance to get to know the scientists behind Drug Hunter. Learn about their backgrounds, why they joined the team, their favorite molecule, and what they're most excited about in drug discovery. Don't miss out on future sessions of this new interactive series! Register here: drughunter.com/coffee-chat-registration Presenter...
Analysis of Successful Hit-to-Clinical Candidate Pairs
Просмотров 1,8 тыс.4 месяца назад
Dean Brown, Ph.D. provides a compelling analysis of 156 clinical candidates published in the Journal of Medicinal Chemistry between 2018 and 2021. 00:00 - About Drug Hunter 04:04 - Introduction of Dr. Dean Brown 11:16 - Presentation commences 48:20 - Q&A Presented by Dean Brown, Ph.D. Jnana Therapeutics with Host Dennis Koester, Ph.D. Drug Hunter Access additional resources and browse previous ...
Relay PI3K Case Study Sneak Peek
Просмотров 6315 месяцев назад
Host Dennis C. Koester, Ph.D. provides a walk-through of one of our popular case studies RLY-2608: An Allosteric Pan-Mutant-Selective PI3Kα Inhibitor Without Hyperglycemia in Preclinical Models. Not at one of the 150 institutions with full Drug Hunter access? Learn how Drug Hunter helps you solve your greatest R&D challenges and request access here: drughunters.com/requestdemo
Drug Hunter Website Demo
Просмотров 3345 месяцев назад
Drug Hunter Website Demo
How GLP-1 Receptor Agonists Evolved from Diabetes to Weight Loss Treatments
Просмотров 4,1 тыс.5 месяцев назад
How GLP-1 Receptor Agonists Evolved from Diabetes to Weight Loss Treatments
A Med Chemist's Guide to Formulation Options to Improve Oral Bioavailability
Просмотров 2,6 тыс.8 месяцев назад
A Med Chemist's Guide to Formulation Options to Improve Oral Bioavailability
Recent Highlights in Covalent Drug Discovery
Просмотров 3,3 тыс.11 месяцев назад
Recent Highlights in Covalent Drug Discovery
Recent Highlights in Targeted Protein Degradation
Просмотров 3,4 тыс.Год назад
Recent Highlights in Targeted Protein Degradation
Not Your Grandparents' Drugs: How Drugs Changed Since the 70's..and What to Do About It
Просмотров 727Год назад
Not Your Grandparents' Drugs: How Drugs Changed Since the 70's..and What to Do About It
Development of a Commercial Manufacturing Process for Sotorasib, a First-in-Class KRASG12C Inhibitor
Просмотров 1,7 тыс.Год назад
Development of a Commercial Manufacturing Process for Sotorasib, a First-in-Class KRASG12C Inhibitor
Visible Light Photoredox Chemistry at Commercial Scale by Kaid Harper
Просмотров 1 тыс.Год назад
Visible Light Photoredox Chemistry at Commercial Scale by Kaid Harper
From "Just Another Kinase" to a New Treatment for Myelofibrosis
Просмотров 1 тыс.Год назад
From "Just Another Kinase" to a New Treatment for Myelofibrosis
Drug Hunter Flash Talks | Strategies to Optimize Unbound Brain Concentrations with Dennis Koester
Просмотров 2,9 тыс.Год назад
Drug Hunter Flash Talks | Strategies to Optimize Unbound Brain Concentrations with Dennis Koester
Drug Hunter Flash Talks | Meet the Founder and CEO of a Billion-Dollar CDMO, Oliver Ju
Просмотров 327Год назад
Drug Hunter Flash Talks | Meet the Founder and CEO of a Billion-Dollar CDMO, Oliver Ju
Recent Highlights in Drug Discovery: Q2/Q3 2022 Part 2
Просмотров 314Год назад
Recent Highlights in Drug Discovery: Q2/Q3 2022 Part 2
Drug Hunter Flash Talk: Recent Highlights in Drug Discovery: Q2/3 '22 September 27th, 2022
Просмотров 423Год назад
Drug Hunter Flash Talk: Recent Highlights in Drug Discovery: Q2/3 '22 September 27th, 2022
Drug Hunter Flash Talk with Prof. Hande Ozdinler, Ph.D. and Prof. Richard B. Silverman, Ph.D.
Просмотров 7582 года назад
Drug Hunter Flash Talk with Prof. Hande Ozdinler, Ph.D. and Prof. Richard B. Silverman, Ph.D.
Drug Hunter Flash Talk with Christian Gampe , Ph.D. August 17th, 12pm EST
Просмотров 6742 года назад
Drug Hunter Flash Talk with Christian Gampe , Ph.D. August 17th, 12pm EST

Комментарии

  • @jaredgain-z6j
    @jaredgain-z6j 4 дня назад

    O'Kon Parks

  • @kbzehamasen3909
    @kbzehamasen3909 26 дней назад

    I couldn't follow you online as the time of the presentation is late night here in Australia.

  • @Truth_Seeker567
    @Truth_Seeker567 27 дней назад

    Thank you Drug Hunter and all the guest speakers for your great help to the medicinal chemists.

  • @kbzehamasen3909
    @kbzehamasen3909 Месяц назад

    very informative and i did enjoy it!

  • @klausdrudolf
    @klausdrudolf Месяц назад

    Excellent overview, providing many insights. Thank you!

  • @user-mp4bc9qp2x
    @user-mp4bc9qp2x 2 месяца назад

    great format. looking forward to more discussions

  • @lipingpettus6541
    @lipingpettus6541 2 месяца назад

    What an amazing review! Thanks Anh.

  • @loveKG26
    @loveKG26 2 месяца назад

    ruclips.net/video/MqWwhggnbyw/видео.htmlsi=A_x1UhMXBwxuM6JB

  • @loveKG26
    @loveKG26 2 месяца назад

    ruclips.net/video/iwvvUabq2QI/видео.htmlsi=xV4LJpShk3o8_nBI

    • @loveKG26
      @loveKG26 2 месяца назад

      ruclips.net/video/VrNZ-yj5QYw/видео.htmlsi=K_eVuUv5OD_T8i3F

    • @loveKG26
      @loveKG26 2 месяца назад

      ruclips.net/video/1JDJoFAzHVI/видео.htmlsi=uh0al2YH3Qb86yiN

  • @loveKG26
    @loveKG26 2 месяца назад

    Treat infections before the take over the human brain with damage and inflammation infection that’s toxic to any human neuron’s….. my neurologist wouldn’t so bye bye lost soul waste less useless service all to make a coin off anti epileptic drugs or many others lol thanks again for letting the issues cause me brain damage so I can have a life long chronic issue needing neurologist prescribed drugs. Nothing to say here about the non obstructive hydrocephalus deemed dementia a lot of the time LOL AGAIN WOW just ignore infection and physiology of the brain. Let it continue to have occurring damage inflammation neurodegenerative issues that could be attenuated but get ignored. Bye useless health services let me rot then. Been there done that seen neurologists up through the I iverstity network first 2014 then by 2020 my ventricles were so large I endured years of hydrocephalus I assume causing the epilepsy they said had no cause. lol again disappointing people look so highly to these places of fake therapy. I couldn’t get the autoimmune work up even though I told my neurologist steroids had me seizure free for almost 2 years again nothing their stupid anti epileptics could do….. Yes I see through them now after 4 neurologists of not ruling out my ear fullness been there for 14 years now same amount of years the seizures …. Chronic infections present with non acute signs and symptoms. I suppose lvl may have mastoiditis all ignored and not ruled out as causing me infection close or in my brain nor the autoimmune…. So just know they like to diagnose and adios quick to do such without proper work ups. No specialists would make sure I had no infection. The side my ears full hurts can’t sleep on it or it feels horrible the next day, hmmm!? Makes one like me think, RETHINK each thing I’m told. Wow even though an MRI SAID IT WAS INFECTION of MASTOID bilateral, 8 years after it became full one day only one ear. Told it’s not infection not an issue not a cause but it feels different the the other side it’s the side seizures are coming from and I see through all these types of people now after 14 years of studying them and their actions through my treatment and it’s only been a pill. Only thing required was to look for brain tumour in my MRI by them….. lol not safe. That’s not the only way physically a seizure can be produced in the human brain. Neurologists also disregard autoimmune issues and any physical issues like with the spine/nervous system…. Not safe for the patient.

  • @invictusfate7195
    @invictusfate7195 2 месяца назад

    Thank you for the nice presentation. Does this mean that current ABeta targeting therapeutics such as donanemab could lead to increased infections in patients under treatment?

    • @loveKG26
      @loveKG26 2 месяца назад

      Wow not good since infections and inflammation can cause amyloid….. leave the infection or inflammation not targeted and get a patient with memory and cognitive issues…. Time to play drug deals…..

  • @invictusfate7195
    @invictusfate7195 2 месяца назад

    Informative presentation, thank you

  • @Truth_Seeker567
    @Truth_Seeker567 2 месяца назад

    Thank you so much Dennis for bringing these great people to share their knowledge.

  • @gagankukreja2068
    @gagankukreja2068 3 месяца назад

    Simply awesome.

  • @gagankukreja2068
    @gagankukreja2068 3 месяца назад

    How much AI assistance the team makes use of while writing these super exciting articles and how do you foresee AI contributing further in your journey. Thanks Gagan Kukreja

    • @drughunter
      @drughunter 3 месяца назад

      Hi Gagan, Thank you so much for this important question. We utilize ML and AI tools to helps us research and filter the vast amount of publications, patents and other sources produced every month. However, our validation and selection process is performed by experts in the field. All of our content is human-written and not generated by generative AI. Looking ahead, we envision further leveraging AI in research and in enhanced search, but it is hard to imaging AI displacing the level of scientific talent on the team!

  • @gagankukreja2068
    @gagankukreja2068 3 месяца назад

    Super inspiring. Besides compiling and sharing the literature, how important is for the Drug Hunter team to share their own independent insights, expert opinion/readout on the molecule being covered. Thanks Gagan Kukreja

    • @drughunter
      @drughunter 3 месяца назад

      Hi Gagan, Thanks for your kind words. At Drug Hunter, our mission is to share the knowledge and learnings acquired by drug discovery teams across the industry with scientists actively engaged in the drug discovery. We aim to facilitate easy access to the primary sources we use, enabling our readers to delve deeper into specific topics if the wish. In "Molecules of the Month" and "Patent Highlights" we follow a rigorous editorial selection process, as detailed by Dennis here: drughunter.com/blog/how-do-you-choose-the-molecules We believe that providing expert opinions is crucial, and we ensure our expressed opinions are well-grounded in facts and thorough analysis. Hope that helps.

  • @user-xs7nn5ip2p
    @user-xs7nn5ip2p 4 месяца назад

    could you list the reference for covalent binding to the backbone amine, it's really interesting! thank you!

  • @rez3vil
    @rez3vil 4 месяца назад

    This was very well summarized.

  • @mario97br
    @mario97br 5 месяцев назад

    Good job nice

  • @petetroglodyte1860
    @petetroglodyte1860 5 месяцев назад

    RLAY PI3K sucks

  • @Truth_Seeker567
    @Truth_Seeker567 8 месяцев назад

    Thank you drug for sharing your talent of clear understanding in organized way.

  • @Finnnicus
    @Finnnicus 9 месяцев назад

    I would love to see more presentations on process stories

  • @user-pe3nq2kz3v
    @user-pe3nq2kz3v 11 месяцев назад

    Hi Dennis. I think there may be a misunderstanding. The EPSA means "exposed PSA" not experimental PSA. Please refer to the literature ACS Med. Chem. Lett. 2014, 5, 1167−1172; ACS Med. Chem. Lett. 2022, 13, 6, 964-971. As you mentioned, the intramolecular hydrogen bond of RMC-6291 may sheild the polarity of morpholine and amide, which results in a similar EPSA with compound 5

    • @drughunter
      @drughunter 11 месяцев назад

      Thank you for your comment! In the original Pfizer paper(s), EPSA (an experimentally determined value from chromatography) was named EPSA in analogy to their previous experimental measure, ELogD (see AMCL 2014). While the "E" wasn't defined in the paper, many started to refer to this as experimental PSA and others exposed PSA, though people are all generally referring to this method.

  • @zefix3133
    @zefix3133 Год назад

    You have to study chemistry for these kind of tasks or is it possible with pharmacy as well?

    • @johnsviewsonspewtube
      @johnsviewsonspewtube Год назад

      A person with a strong background in Organic Synthesis will best succeed in the area of process chemistry. Significant training in a Ph.D program along with post-doctoral training focusing in total synthesis of complex natural products is a likely optimal route for one to pursue, however, that's not to say that a chemist with extensive training in organic methodologies development and applications to total synthesis of natural products could not success just as well. I came from a Medicinal Chemistry graduate program and we had many people with Pharmacy backgrounds who succeeded very well in synthetic chemistry careers. Overall, it's important to understand a breadth of organic reactions, mechanistic understanding and hands on applications from milligram to multi-gram scale. To transition to process, a deep understanding of physical organic chemistry becomes important since these considerations must be accounted for when working on kilogram scales. I worked in a pharma med chem lab for a decade and now in project management for the federal government, and hold process chemists in the highest respects for their elegance and optimization of initial synthetic routes. Good luck in you endeavors ~John

  • @noriegajoel599
    @noriegajoel599 Год назад

    What would you have chosen, to live with herpes virus, CFS/ME (etc)forever or go for the herpes virus, CFS/ME proven medicine that has worked immensely in curing people from _Dr Madida_ /-/\-\